Skip to content
Buy This GLP
← Research
Evidence

Tirzepatide Weight Loss in Women With PCOS: A UK Cohort of 54,114 Women

In a UK cohort, 40 women with self-reported PCOS averaged 19.40% weight loss after 10 months on tirzepatide. The mean was 18.74% among 397 women without self-reported PCOS.

Editorial profile: Carla MedinaBuy This GLP Editorial Team6 min read
Where the headline number comes fromwomen in the cohort54,114with PCOS4,241with a 10-month figure40−19.40% is the mean of those forty.The study combined different lengths of follow-up.

This study adds observational evidence to the broader research on GLP-1 treatment for PCOS by comparing women prescribed the same drug. Participants reported their PCOS status and logged their own weights. The study did not assess whether tirzepatide improved ovulation, hormone levels, or other PCOS symptoms.[1]

Weight change among women who reached 10 months

At month 10, the 40 women with self-reported PCOS who reached that point on treatment lost a mean 19.40% of their starting weight (95% confidence interval, 16.42% to 22.38%). The 397 women without self-reported PCOS lost a mean 18.74% (95% confidence interval, 17.81% to 19.67%). The difference was not statistically significant (p = 0.68). That comparison leaves room for a true difference between the groups.[1]

Why the follow-up group was smaller

The study included women who began treatment between February 2024 and January 2025, and the average follow-up was 2.28 months. Later starters could run out of observation time. Others stopped treatment. Table 2 reports who contributed at each visit, and supplemental figures show follow-up and censoring in both groups.[1]

What the 57.66% figure measures

The authors used Kaplan–Meier analysis to estimate the chance of reaching at least 20% weight loss by month 10. For the self-reported PCOS group, the estimate was 57.66% (95% confidence interval, 47.44% to 68.29%). The analysis used the timing of recorded weight loss milestones and accounted for when follow-up ended. It drew from participants as they contributed follow-up, beyond the 40 women in the month-10 mean. This estimate depends on the assumptions used to account for incomplete follow-up.[1]

The digital engagement finding

Among women with self-reported PCOS, digital engagement was associated with 3.42 percentage points more weight loss by month 10 in an adjusted analysis (95% confidence interval, 1.71 to 5.12 percentage points, p < 0.001). Engagement included a coaching session, weekly weight tracking on average, and use of the app’s information materials. When weighing evidence on GLP-1 coaching, consider that participants chose whether to engage and that motivation or treatment adherence may partly explain the difference.[1]

Funding and author disclosures

The paper reported no relevant funding. Four authors worked for Menwell Ltd, which operates Voy, the UK service that supplied the data. The fifth disclosed consulting or speaking fees from several drugmakers, including Eli Lilly, and grants paid to his university outside this study.[1]

Frequently asked

Does tirzepatide work as well if you have PCOS?
Among those who reached 10 months on treatment, the study found no statistically significant difference in mean weight loss between 40 women with self-reported PCOS and 397 without it. The study did not establish equivalence.
How many women were actually measured at ten months?
The month-10 means came from 40 women with self-reported PCOS and 397 without it. The full cohort included 54,114 women with varying lengths of follow-up.
Does using the app help?
Digital engagement was associated with 3.42 percentage points more weight loss among women with self-reported PCOS. Participants chose whether to engage, so the study cannot isolate an app or coaching effect.
Was the PCOS diagnosis confirmed?
No. It was self-reported to a commercial weight-management service rather than verified clinically.

Sources

  1. [1] Clift AK, et al. (2026). Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome Journal of the Endocrine Society. PMID 42634795

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence